CINECA IRIS Institutional Research Information System

BARRESI, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.477
AS - Asia 4.798
EU - Europa 4.000
SA - Sud America 595
Continente sconosciuto - Info sul continente non disponibili 386
AF - Africa 260
OC - Oceania 33
Totale 19.549
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.009
IT - Italia 1.746
SG - Singapore 1.399
CN - Cina 1.108
VN - Vietnam 924
HK - Hong Kong 577
BR - Brasile 454
DE - Germania 411
SE - Svezia 408
CA - Canada 329
FR - Francia 225
GB - Regno Unito 202
AT - Austria 195
BG - Bulgaria 180
FI - Finlandia 168
JP - Giappone 165
RU - Federazione Russa 149
IN - India 145
KR - Corea 73
TR - Turchia 68
BD - Bangladesh 59
NL - Olanda 57
CI - Costa d'Avorio 54
MX - Messico 54
PL - Polonia 48
IQ - Iraq 44
PK - Pakistan 44
NG - Nigeria 42
UA - Ucraina 41
AR - Argentina 39
SN - Senegal 39
ES - Italia 34
ZA - Sudafrica 34
AU - Australia 31
BE - Belgio 31
UZ - Uzbekistan 26
EG - Egitto 23
SA - Arabia Saudita 23
CH - Svizzera 22
EC - Ecuador 22
IL - Israele 21
CO - Colombia 20
VE - Venezuela 20
ID - Indonesia 19
KE - Kenya 18
CZ - Repubblica Ceca 15
MA - Marocco 15
TT - Trinidad e Tobago 15
CR - Costa Rica 14
JO - Giordania 13
LT - Lituania 12
JM - Giamaica 11
PY - Paraguay 11
AZ - Azerbaigian 10
DZ - Algeria 10
PR - Porto Rico 10
AE - Emirati Arabi Uniti 9
CL - Cile 8
HU - Ungheria 8
IE - Irlanda 8
KZ - Kazakistan 8
BO - Bolivia 7
ET - Etiopia 7
MY - Malesia 7
OM - Oman 7
PH - Filippine 7
NI - Nicaragua 6
PE - Perù 6
TW - Taiwan 6
GE - Georgia 5
LB - Libano 5
RO - Romania 5
UY - Uruguay 5
AL - Albania 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
EE - Estonia 4
GT - Guatemala 4
IR - Iran 4
PA - Panama 4
SC - Seychelles 4
SV - El Salvador 4
BB - Barbados 3
BH - Bahrain 3
GY - Guiana 3
HN - Honduras 3
PT - Portogallo 3
SI - Slovenia 3
BQ - ???statistics.table.value.countryCode.BQ??? 2
BZ - Belize 2
CW - ???statistics.table.value.countryCode.CW??? 2
GR - Grecia 2
HR - Croazia 2
KG - Kirghizistan 2
KW - Kuwait 2
MK - Macedonia 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
Totale 19.128
Salva come PNG Salva come JPEG
Città #
Ashburn 1.195
Singapore 769
San Jose 642
Serra 561
Hong Kong 543
Dallas 493
Santa Clara 427
Woodbridge 395
Fairfield 363
Ann Arbor 343
Chandler 333
Council Bluffs 322
Houston 317
Ho Chi Minh City 273
Hanoi 233
Shanghai 222
New York 213
Beijing 200
Los Angeles 198
Sofia 179
Seattle 174
Vienna 167
Ottawa 152
Wilmington 133
Boardman 126
Frankfurt am Main 126
Pisa 119
Princeton 117
Milan 114
Hefei 110
Tokyo 108
Cambridge 106
Helsinki 85
Lauterbourg 84
Munich 81
Lawrence 78
Medford 73
Des Moines 72
Seoul 67
Florence 56
Abidjan 54
São Paulo 53
Buffalo 49
Da Nang 49
London 49
Redondo Beach 49
Dearborn 48
Turku 47
Rome 43
Rho 41
Bremen 40
Dakar 39
Lagos 39
Lucca 37
Haiphong 36
Istanbul 36
Warsaw 35
Livorno 33
Toronto 32
Nanjing 31
Atlanta 30
Brussels 30
Baltimore 29
Montreal 29
Columbus 28
Orem 27
Chicago 26
Dong Ket 25
Phoenix 25
Tashkent 25
San Diego 24
Jacksonville 23
Sydney 22
Denver 21
Boulder 20
Paris 20
Pune 20
North Bergen 19
Pessac 19
Brooklyn 18
Fort Wayne 18
Manchester 18
Ogden 18
Johannesburg 17
Nuremberg 17
Amsterdam 16
Cascina 16
Changsha 15
Dhaka 15
Fuzhou 15
Guangzhou 15
Izmir 15
Mexico City 15
Philadelphia 15
Pistoia 15
Stockholm 15
Brasília 14
Düsseldorf 14
Redwood City 14
The Dalles 14
Totale 12.000
Salva come PNG Salva come JPEG
Nome #
Metformin conjugates and therapeutic use thereof 412
TSPO ligand residence time influences human glioblastoma multiforme cell death/life balance 353
18 kDa TSPO targeting drives polarized human microglia towards a protective and restorative neurosteroidome profile 332
Iminothioethers as Hydrogen Sulfide Donors: From the Gasotransmitter Release to the Vascular Effects 317
Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas 292
Apoptosis Therapy in Cancer: The First Single-molecule Co-activating p53 and the Translocator Protein in Glioblastoma 290
TSPO PIGA ligands promote neurosteroidogenesis and human astrocyte well-being 289
Benzofuroxane Derivatives as Multi Effective Agents for the Treatment of Cardiovascular Diabetic Complications. Synthesis, Functional Evaluation, and Molecular Modeling Studies 287
Two mixed valence diruthenium(ii,iii) isomeric complexes show different anticancer properties 273
Deepening the Topology of the Translocator Protein Binding Site by Novel N,N-Dialkyl-2-arylindol-3-ylglyoxylamides 261
The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities 259
Translocator Protein 18-kDa: a promising target to treat neuroinflammation-related degenerative diseases 259
A complex bearing TSPO PIGA ligand coordinated to the [Au(PEt3)]+ pharmacophore is highly cytotoxic against ovarian cancer cells 254
Allosteric modulators of human A2B adenosine receptor. 250
Sulfonamides incorporating heteropolycyclic scaffolds show potent inhibitory action against carbonic anhydrase isoforms I, II, IX and XII 247
TSPO Radioligands for Neuroinflammation: An Overview 246
TSPO ligand residence time: a new parameter to predict compound neurosteroidogenic efficacy 245
A mixed-valence diruthenium(ii,iii) complex endowed with high stability: from experimental evidence to theoretical interpretation 238
Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of non-camptothecin Topoisomerase I (Top1) inhibitors 229
A cyanine-based NIR fluorescent Vemurafenib analog to probe BRAFV600E in cancer cells 228
Long lasting inhibition of Mdm2-p53 interaction potentiates mesenchymal stem cell differentiation into osteoblasts 228
Benzothiopyranoindole- and pyridothiopyranoindole-based antiproliferative agents targeting topoisomerases 226
An update into the medicinal chemistry of translocator protein (TSPO) ligands 225
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: A Novel Template for the Design of Highly Selective A(2B) Adenosine Receptor Antagonists. 224
Discovery of Pyrido[3′,2′:5,6]thiopyrano[4,3- d]pyrimidine-Based Antiproliferative Multikinase Inhibitors 224
New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors 222
Arylthioamides as H2S Donors:l-Cysteine-Activated Releasing Properties and Vascular Effects in Vitro and in Vivo 221
Drug-target Residence Time: a key parameter in glial responses to TSPO ligands 213
Targeting TSPO Reduces Inflammation and Apoptosis in an In Vitro Photoreceptor-Like Model of Retinal Degeneration 212
Novel fluorescent triazinobenzimidazole derivatives as probes for labelling human A1 and A2B adenosine receptor subtypes 212
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A(2B) adenosine receptor antagonists 211
Residence Time (RT), a new parameter to predict neurosteroidogenic efficacy of Translocator Protein (TSPO) ligands: N,N-dialkyl-2-arylindol-3-ylglyoxylamides, a case study 211
New antiproliferative agents derived from tricyclic 3,4-dihydrobenzo[4,5]imidazo[1,2-a][1,3,5]triazine scaffold: synthesis and pharmacological effects 210
Translocator protein (tspo) ligand residence time: a new parameter to predict neurosteroidogenic efficacy for n,n-dialkyl-2-arylindol-3-ylglyoxylamides (PIGAs) 209
Novel positive allosteric modulators of A2B adenosine receptor acting as bone mineralisation promoters 205
Discovery of the First-in-Class Dual TSPO/Carbonic Anhydrase Modulators with Promising Neurotrophic Activity 204
An irreversible ligand of the 18 kDa Translocator Protein induces rapidly ΔΨm collapse and activates apoptosis in human glioblastoma multiforme cells. 201
Targeting the 18-kDa translocator protein: Recent perspectives for neuroprotection 199
4-Substituted Benzenesulfonamides Incorporating Bi/Tricyclic Moieties Act as Potent and Isoform-Selective Carbonic Anhydrase II/IX Inhibitors 199
Inhibition studies on carbonic anhydrase isoforms I, II, IV and IX with N-arylsubstituted secondary sulfonamides featuring a bicyclic tetrahydroindazole scaffold 199
Modulation of A2B adenosine receptor by 1-benzyl-3-ketoindole derivatives 196
Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells 193
Modulation of A2B Adenosine Receptor by 1-Benzyl-3-ketoindole Derivatives 192
De novo neurosteroidogenesis in human microglia: Involvement of the 18 kda translocator protein 190
Allosteric modulation of A2B adenosine receptors potentiate the effects of orthosteric receptor agonists to promote mesenchymal stem cell differentiation to osteoblasts. 188
Exploiting the 4-Phenylquinazoline Scaffold for the Development of High Affinity Fluorescent Probes for the Translocator Protein (TSPO) 188
Unbinding of Translocator Protein 18 kDa (TSPO) Ligands: From in Vitro Residence Time to in Vivo Efficacy via in Silico Simulations 187
Carbonic anhydrase activation profile of indole-based derivatives 187
Iminothioethers as a novel class of H2S-donor: gasotransmitter release and vascular effects 186
Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents 183
Refinement of the translocator protein pharmacophore/receptor model via structure-activity relationships of novel N,N-dialkylindolylglyoxylamides 183
Targeting the Translocator Protein (18 kDa) in Cardiac Diseases: State of the Art and Future Opportunities 173
2-(phenylsulphonamido)-pyrazole derivatives as carbonic anhydrase inhibitors 172
Studies on enantioselectivity of chiral 4-acetylamino-6-alkyloxy-2-alkylthiopyrimidines acting as antagonists of the human A3 adenosine receptor 171
Dual Targeting Topoisomerase/G-Quadruplex Agents in Cancer Therapy-An Overview 170
Interaction of the irreversible ligand IRDE-MPIGA with TSPO (18 KDa): new insight on TSPO role in tumor cells. 170
Indol-3-ylglyoxylamide as Privileged Scaffold in Medicinal Chemistry 170
Allosteric Modulators of Adenosine Receptors 168
Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin Topoisomerase I (top1) inhibitors 168
Structure-Activity Relationship Refinement and Further Assessment of 4-Phenylquinazoline-2-carboxamide Translocator Protein Ligands as Antiproliferative Agents in Human Glioblastoma Tumors. 168
3-Aryl-1,2,4-triazino-4,3-abenzimidazol-4(10H)-one: a novel template for the design of highly selective A2B adenosine receptor antagonists 166
Tetrahydroquinazole-based secondary sulphonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IV, and IX, and computational studies 164
Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs 163
Cancer Immunotherapy: An Overview on Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021) 162
Anti-Proliferative Properties of the Novel Hybrid Drug Met-ITC, Composed of the Native Drug Metformin with the Addition of an Isothiocyanate H2S Donor Moiety, in Different Cancer Cell Lines 161
Benzoxadiazole Derivatives: Atypical Inhibitors of Aldose Reductase 160
Allosterism vs. Orthosterism: Recent Findings and Future Perspectives on A2B AR Physio-Pathological Implications 160
Diruthenium(ii,iii) paddlewheel complexes: effects of bridging and axial ligands on anticancer properties 160
From conventional therapy to novel nano-based approaches. A focus on prostate cancer 158
Glioblastoma multiforme: induction of mitochondria-mediated apoptotic pathway by simultaneous pharmacological activation of TSPO (18KDa) and p53. 158
Design and synthesis of novel indolylglyoxylamide derivatives as molecular probes for 18 KDa translocator protein (TSPO) 158
Oxaliplatin(IV) Prodrugs Functionalized with Gemcitabine and Capecitabine Induce Blockage of Colorectal Cancer Cell Growth - An Investigation of the Activation Mechanism and Their Nanoformulation 155
Refinement of the Mitochondrial Translocator Protein Pharmacophore/Receptor Model via Structure-activity Relationships of Novel N,N-Dialkylindolylglyoxylamides 152
N,N-dialkyl-5-isothiocyanato-2-phenylindol-3-ylglyoxylamide: an irreversible ligand to study the translocator protein 152
Pursuing Polypharmacology: Benzothiopyranoindoles as G-Quadruplex Stabilizers and Topoisomerase I Inhibitors for Effective Anticancer Strategies 150
Development of novel indole-based tdp1 inhibitors for anticancer therapy 148
Development of a New A2B Adenosine Receptors PET ligand: 3- Phenyl-1-[11C]methyl-3- aryl[1,2,4]triazino[4,3 -a]benzimidazol-4(10H)-one 147
Refinement of the Mitochondrial Translocator Protein Pharmacophore/Receptor Model via Structure-activity Relationships of Novel N,N-Dialkylindolylglyoxylamides 145
Enhancing the Anticancer Activity of Attenuated Listeria monocytogenes by Cell Wall Functionalization with “Clickable” Doxorubicin 144
2-(Phenylamino)-7,8-dihydroquinazolin-5(6H)-one, a promising scaffold for MAO-B inhibitors with potential GSK3β targeting 143
Discovery of N-substituted-2-oxoindolin benzoylhydrazines as c-MET/SMO modulators in EGFRi-resistant non-small cell lung cancer 143
Iminothioethers As A Novel Class Of H2s-Donor: Gasotransmitter Release And Vascular Effects 139
New suitable scaffolds for the development of non camptothecin topoisomerase I (Top1) inhibitors 139
Essential Principles and Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging 139
Carbonic Anhydrase Activators for Neurodegeneration: An Overview 134
Indole-Based Compounds in the Development of Anti-Neurodegenerative Agents 133
Indole-based modulators of p53/MDM2 interaction as antitumoral agents 130
Novel 2-substituted-benzimidazole-6-sulfonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IX and XII and molecular docking studies 128
Strategies for the improvement of metal-based chemotherapeutic treatments 128
H2S-releasing properties of new thioamide derivatives 126
Drug repurposing meets DNA independent pathways: targeting alternative substrates for anticancer therapy 118
Modulation of PAR1 signaling by benzimidazole compounds 111
Lead optimization of a novel molecular scaffold in search for novel MMP-13 inhibitors 110
Enriching the arsenal of pharmacological tools against mical2 110
Indole-based modulators of p53/MDM2 interaction as antitumoral agents 109
Refinement of the Mitochondrial Translocator Protein Pharmacophore/Receptor Model via Structure-activity Relationships of Novel N,N-Dialkylindolylglyoxylamides. 109
Radiosynthesis of the TSPO 18 kDa PET Radiotracer [18F](R)-PK14105 108
Tyrosine kinase inhibitors (TKIs) for ovarian cancer treatment: from organic to inorganic chemotherapeutics towards selectivity-a perspective overview 104
Labeling of TSPO PET radioligands by [18F]fluorination of diarylsulfoxide precursors 99
Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders 97
Totale 18.939
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.347
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.347
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022813 0 0 0 0 137 166 55 46 34 34 45 296
2022/20231.532 162 207 127 146 151 190 14 97 324 13 71 30
2023/20241.123 59 72 104 40 119 249 129 44 11 30 131 135
2024/20253.916 31 111 56 203 347 414 268 136 361 449 439 1.101
2025/20265.694 254 582 560 463 539 377 1.396 245 370 492 215 201
2026/20272.563 147 701 791 796 128 0 0 0 0 0 0 0
Totale 19.549